MCID: PNC013
MIFTS: 47

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 15
Carcinoma, Pancreatic Ductal 44 73
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 55
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD10 33 C25.3
ICD9CM 35 157.3
MeSH 44 D021441
SNOMED-CT 68 93939009

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to microcystic adenoma and cystadenocarcinoma. An important gene associated with Pancreatic Ductal Carcinoma is MUC6 (Mucin 6, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Paclitaxel and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and ovary, and related phenotypes are cellular and neoplasm

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 267)
# Related Disease Score Top Affiliating Genes
1 microcystic adenoma 30.3 MUC1 MUC6
2 cystadenocarcinoma 29.6 KRT7 MUC1 MUC2 TP53 VEGFA
3 adenocarcinoma 29.1 CDKN2A MUC1 SMAD4 TP53 VEGFA
4 pancreatic cancer 28.9 CDKN2A MUC1 MUC2 SMAD4 TP53 VEGFA
5 pancreatic adenosquamous carcinoma 11.3
6 nodular hidradenoma 10.3 KRT7 MUC1
7 parachordoma 10.3 KRT7 MUC1
8 sertoli-leydig cell tumor 10.3 KRT7 MUC1
9 mucinous ovarian cystadenoma 10.3 KRT7 MUC1
10 hidradenoma 10.3 KRT7 MUC1
11 spindle cell sarcoma 10.3 KRT7 MUC1
12 secretory meningioma 10.3 KRT7 MUC1
13 sclerosing hemangioma 10.3 KRT7 MUC1
14 middle ear adenoma 10.3 KRT7 MUC1
15 lipoadenoma 10.3 KRT7 MUC1
16 monophasic synovial sarcoma 10.3 KRT7 MUC1
17 meconium ileus 10.3 MUC1 MUC2
18 epithelioid hemangioendothelioma 10.3 MUC1 VEGFA
19 pancreatic serous cystadenoma 10.3 KRT7 VEGFA
20 superior mesenteric artery syndrome 10.3 MUC2 MUC6
21 brachydactyly, type e1 10.3 KRT20 MUC1
22 villous adenoma 10.3 KRT20 MUC1
23 dendritic cell tumor 10.2 KRT20 MUC1
24 jejunal adenocarcinoma 10.2 KRT20 KRT7
25 immune system organ benign neoplasm 10.2 KRT20 KRT7
26 bladder lymphoma 10.2 KRT20 KRT7
27 chronic cystitis 10.2 KRT20 KRT7
28 thymus lipoma 10.2 KRT20 KRT7
29 rectum adenocarcinoma 10.2 KRT20 KRT7
30 prostatic acinar adenocarcinoma 10.2 KRT20 KRT7
31 bladder adenocarcinoma 10.2 KRT20 KRT7
32 linitis plastica 10.2 KRT20 KRT7
33 infiltrative basal cell carcinoma 10.2 KRT20 KRT7
34 medulloepithelioma 10.2 KRT20 KRT7
35 thymus adenocarcinoma 10.2 KRT20 KRT7
36 ovarian cystic teratoma 10.2 KRT20 KRT7
37 adenoid squamous cell carcinoma 10.2 KRT20 KRT7
38 gastric diffuse adenocarcinoma 10.2 KRT20 KRT7
39 lung acinar adenocarcinoma 10.2 KRT20 KRT7
40 intratubular embryonal carcinoma 10.2 KRT20 KRT7
41 horseshoe kidney 10.2 KRT20 KRT7
42 small cell carcinoma of the bladder 10.2 KRT20 KRT7
43 meibomian cyst 10.2 KRT20 KRT7
44 chronic myocardial ischemia 10.2 TYMP VEGFA
45 papilloma of choroid plexus 10.2 MUC1 TP53
46 chordoid glioma 10.2 MUC1 TP53
47 cerebral primitive neuroectodermal tumor 10.2 MUC1 TP53
48 prostate squamous cell carcinoma 10.2 KRT7 TP53
49 mixed cell type cancer 10.2 KRT7 TP53
50 female reproductive endometrioid cancer 10.2 KRT7 TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.56 CDKN2A KRT7 MUC2 SMAD4 TGM2 TP53
2 neoplasm MP:0002006 9.1 CDKN2A MUC2 SMAD4 TGM2 TP53 VEGFA

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
3
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
4 Antiviral Agents Phase 3,Phase 1,Phase 2
5 Immunologic Factors Phase 3,Phase 1,Phase 2
6 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
7 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
8 Antimetabolites, Antineoplastic Phase 3,Phase 1,Phase 2
9 Antimetabolites Phase 3,Phase 1,Phase 2
10 Anti-Infective Agents Phase 3,Phase 1,Phase 2
11 Antimitotic Agents Phase 3,Phase 1,Phase 2
12 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
13 Protective Agents Phase 3
14 Adjuvants, Immunologic Phase 3
15 acivicin Phase 3
16 Viscosupplements Phase 3
17
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
18
Pancrelipase Approved, Investigational Phase 1, Phase 2 53608-75-6
19
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
20
Doxil Approved June 1999 Phase 2 31703
21
Tremelimumab Investigational Phase 2 745013-59-6
22 Topoisomerase Inhibitors Phase 2
23 Antibiotics, Antitubercular Phase 2
24 Anti-Bacterial Agents Phase 2
25 Immunoglobulins Phase 1, Phase 2,Phase 2
26 Antibodies Phase 1, Phase 2,Phase 2
27 Antibodies, Monoclonal Phase 1, Phase 2,Phase 2
28 pancreatin Phase 1, Phase 2
29 Cola Phase 1, Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
2 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
3 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
4 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
5 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer Completed NCT01839487 Phase 2 PEGPH20+nab-paclitaxel+gemcitabine;nab-paclitaxel + gemcitabine
6 QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Completed NCT01040000 Phase 1, Phase 2 NPC-1C/NEO-102
7 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
8 A Dose-Finding Study of MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Completed NCT02259114 Phase 1 MK-8628

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

41
Pancreas, Lung, Ovary, Cervix, Thymus, Small Intestine, Appendix

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

19
The Pancreatic Duct

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 82)
# Title Authors Year
1
Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. ( 29409514 )
2018
2
Routine MRI With DWI Sequences to Detect Liver Metastases in Patients With Potentially Resectable Pancreatic Ductal Carcinoma and Normal Liver CT: A Prospective Multicenter Study. ( 30240298 )
2018
3
The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms. ( 27458977 )
2017
4
Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration. ( 28099249 )
2017
5
Adjuvant treatment for pancreatic ductal carcinoma. ( 28639051 )
2017
6
Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation. ( 29273724 )
2017
7
Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma. ( 28927124 )
2017
8
Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. ( 29254283 )
2017
9
Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. ( 27552832 )
2016
10
Efficacy of contrast-enhanced harmonic endoscopic ultrasonography in the diagnosis of pancreatic ductal carcinoma. ( 27184637 )
2016
11
A case report on metastatic pancreatic tumor from pulmonary adenocarcinoma that difficult to differentiate from primary pancreatic ductal carcinoma. ( 27498937 )
2016
12
Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. ( 27237099 )
2016
13
Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma. ( 26261495 )
2015
14
Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. ( 24845232 )
2014
15
Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. ( 24901166 )
2014
16
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report. ( 24778053 )
2014
17
Pancreatic intraglandular metastasis predicts poorer outcome in postoperative patients with pancreatic ductal carcinoma. ( 23648465 )
2013
18
Clinicopathologic assessment of pancreatic ductal carcinoma located at the head of the pancreas, in relation to embryonic development. ( 22228049 )
2012
19
Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. ( 22892044 )
2012
20
Preoperative platelet-lymphocyte ratio in resected pancreatic ductal carcinoma: is it meaningful? ( 20579970 )
2012
21
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. ( 21841817 )
2012
22
Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. ( 22190076 )
2012
23
Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension. ( 22562451 )
2012
24
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. ( 21224073 )
2011
25
Cytologic features of pancreatic intraepithelial neoplasia and pancreatitis: potential pitfalls in the diagnosis of pancreatic ductal carcinoma. ( 20730891 )
2011
26
Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with I^-catenin in tumor progression. ( 21466814 )
2011
27
Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. ( 21272935 )
2011
28
Asymptomatic curable pancreatic ductal carcinoma detected during the follow-up of pancreatic cysts distinct from carcinoma. ( 26190721 )
2011
29
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. ( 19856421 )
2010
30
Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. ( 18845377 )
2009
31
Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. ( 19248224 )
2009
32
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. ( 19020717 )
2008
33
Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. ( 18505086 )
2008
34
Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. ( 17378244 )
2007
35
Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. ( 17003643 )
2006
36
Pancreatic ductal carcinoma: from the bench to the bedside. ( 16998251 )
2006
37
Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. ( 17072983 )
2006
38
Contrast-enhanced sonography of pancreatic ductal carcinoma using agent detection imaging. ( 27277616 )
2006
39
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. ( 16125925 )
2005
40
Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. ( 16053509 )
2005
41
Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy. ( 15951559 )
2005
42
Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. ( 16335935 )
2005
43
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? ( 16018800 )
2005
44
Factors predicting recurrence after resection of pancreatic ductal carcinoma. ( 15968250 )
2005
45
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. ( 15985168 )
2005
46
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. ( 16136352 )
2005
47
Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. ( 15084983 )
2004
48
Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. ( 14745573 )
2004
49
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. ( 15258755 )
2004
50
Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. ( 14707723 )
2004

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 CDKN2A SMAD4 TP53 VEGFA
2 12.59 CDKN2A SMAD4 TP53 VEGFA
3
Show member pathways
12.46 CDKN2A MUC2 SMAD4 TP53
4
Show member pathways
12.01 MUC1 MUC2 MUC6
5 11.95 SMAD4 TP53 VEGFA
6 11.87 SMAD4 TP53 VEGFA
7
Show member pathways
11.82 MUC1 MUC2 MUC6
8 11.69 CDKN2A SMAD4 TP53
9 11.67 MUC1 TP53 VEGFA
10
Show member pathways
11.62 MUC1 MUC2 MUC6
11 11.57 CDKN2A SMAD4 TP53
12 11.54 CDKN2A SMAD4 TP53 VEGFA
13 11.23 CDKN2A TP53 VEGFA
14 11.14 SMAD4 TP53 VEGFA
15 11.1 CDKN2A TP53
16 10.99 CDKN2A SMAD4 TP53 VEGFA
17 10.89 CDKN2A TP53
18
Show member pathways
10.88 CDKN2A TP53
19 10.85 MUC2 SMAD4
20 10.79 CDKN2A TP53 TYMP VEGFA

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell growth GO:0030308 9.54 CDKN2A SMAD4 TP53
2 maintenance of gastrointestinal epithelium GO:0030277 9.32 MUC2 MUC6
3 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP53
4 replicative senescence GO:0090399 9.16 CDKN2A TP53
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.13 MUC1 MUC2 MUC6
6 O-glycan processing GO:0016266 8.8 MUC1 MUC2 MUC6

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....